Hake A - Search Results

1

Association of an interleukin 1 alpha polymorphism with Alzheimer's disease.

Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmüller F, Müller U, Kurz A, Zimmer R, Evans RM, Hake A, Gasser T, Oertel WH, Griffin WS, Paul SM, Farlow MR. Du Y, et al. Among authors: hake a. Neurology. 2000 Aug 22;55(4):480-3. doi: 10.1212/wnl.55.4.480. Neurology. 2000. PMID: 10953177

2

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial.

Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, McCleary CA, Klein RA, Hake AM, Farlow MR. Henderson VW, et al. Among authors: hake am. Neurology. 2000 Jan 25;54(2):295-301. doi: 10.1212/wnl.54.2.295. Neurology. 2000. PMID: 10668686 Clinical Trial.

3

Alpha2 macroglobulin and the risk of Alzheimer's disease.

Dodel RC, Du Y, Bales KR, Gao F, Eastwood B, Glazier B, Zimmer R, Cordell B, Hake A, Evans R, Gallagher-Thompson D, Thompson LW, Tinklenberg JR, Pfefferbaum A, Sullivan EV, Yesavage J, Alstiel L, Gasser T, Farlow MR, Murphy GM Jr, Paul SM. Dodel RC, et al. Among authors: hake a. Neurology. 2000 Jan 25;54(2):438-42. doi: 10.1212/wnl.54.2.438. Neurology. 2000. PMID: 10668709

4

Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene.

Murrell JR, Hake AM, Quaid KA, Farlow MR, Ghetti B. Murrell JR, et al. Among authors: hake am. Arch Neurol. 2000 Jun;57(6):885-7. doi: 10.1001/archneur.57.6.885. Arch Neurol. 2000. PMID: 10867787

5

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R. Farlow MR, et al. Among authors: hake a. Arch Neurol. 2001 Mar;58(3):417-22. doi: 10.1001/archneur.58.3.417. Arch Neurol. 2001. PMID: 11255445 Clinical Trial.

6

New concepts in the drug therapy of Alzheimer's disease.

Hake AM, Farlow MR. Hake AM, et al. Expert Opin Pharmacother. 2001 Dec;2(12):1975-83. doi: 10.1517/14656566.2.12.1975. Expert Opin Pharmacother. 2001. PMID: 11825329 Review.

7

The treatment of Alzheimer's disease: the approach from a clinical specialist in the trenches.

Hake AM. Hake AM. Semin Neurol. 2002 Mar;22(1):71-4. doi: 10.1055/s-2002-33050. Semin Neurol. 2002. PMID: 12170395 Review.

8

On the horizon: pathways for drug development in Alzheimer's disease.

Hake AM, Farlow MR. Hake AM, et al. Clin Geriatr Med. 2004 Feb;20(1):141-52. doi: 10.1016/S0749-0690(03)00073-9. Clin Geriatr Med. 2004. PMID: 15062492 No abstract available.

9

Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort.

Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, Foroud T, Pankratz N, Moore JH, Sloan CD, Huentelman MJ, Craig DW, Dechairo BM, Potkin SG, Jack CR Jr, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative. Shen L, et al. Neuroimage. 2010 Nov 15;53(3):1051-63. doi: 10.1016/j.neuroimage.2010.01.042. Epub 2010 Jan 25. Neuroimage. 2010. PMID: 20100581 Free PMC article.

10

Use of anticholinergics and the risk of cognitive impairment in an African American population.

Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, Murrell JR, Unverzagt FW, Hake A, Smith-Gamble V, Hall K. Campbell NL, et al. Among authors: hake a. Neurology. 2010 Jul 13;75(2):152-9. doi: 10.1212/WNL.0b013e3181e7f2ab. Neurology. 2010. PMID: 20625168 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters